The Hunt for Dry Eye Instigators

Total Page:16

File Type:pdf, Size:1020Kb

The Hunt for Dry Eye Instigators RCCL MAY 2014 REVIEW OF CORNEA & CONTACT LENSES EARNARN 2 CECE CREDITSREEDITDITS The Hunt for Dry Eye Instigators Treatment optionsns thatththatt targettarargeet inflininfl ammatoryamammamatotory mmediatorseeddiai totorsr in the tear fi lm may help clinicians achieve victory over this often diffi cult to manage condition. Supplement to Controlling the ocular immune response • bring sjÖgren’s out of the shadows 001_rcl0514_cover.indd 1 4/25/14 2:47 PM THIS IS WHY our new daily disposable multifocal contact lens is designed to perform at every distance and refreshes with every blink—no matter what the day may bring. PRECISION PROFILE Design WITH BLINK-ACTIVATED MOISTURE NEAR IN TE NEW DAILIES® AquaComfort Plus® Multifocal TERMEDIA contact lenses are designed to deliver clear binocular vision and refreshing comfort. D ISTANCE PRECISION PROFILE BLINK-ACTIVATED SUCCESSFUL WEAR DESIGN MOISTURE Clear vision and Smooth, uninterrupted Moisture is released comfort throughout transitions from near with every blink, the day. to intermediate, which helps result to distance. in a stable tear fi lm. NEW Visit myalcon.com Featuring the same Precision Profi le Design as AIR OPTIX® AQUA Multifocal— the #1 multifocal contact lens.1 PERFORMANCE DRIVEN BY SCIENCE™ Reference: 1. Based on third-party industry report, 12 months ending March 2013, Alcon data on fi le. See product instructions for complete wear, care, and safety information. © 2013 Novartis 11/13 DAM13014JAD RCCL0514_Alcon Dailies.indd 1 4/15/14 2:09 PM contents Review of Cornea & Contact Lenses | May 2014 departments 4 News Review A New Treatment for Allergic Conjunctivitis?; features A Balanced Dry Eye Diet Controlling the 6 My Perspective Ocular Immune Response LSCD—It May Be the Lenses We must strive to limit its untoward eff ects without undermining its essential role in By Joseph P. Shovlin, OD protection and healing. 12 By Aaron Bronner, OD 7 Lens Care Insights Wash Away Your Old Hygiene Strategy It’s Time to Bring Sjögren’s By Christine W. Sindt, OD Out of the Shadows This autoimmune disease can go undiagnosed for years. By working closely with other health Pharma Science & Practice care providers, we may be able to detect it in 8 its earliest stages. 16 By Arthur B. Epstein, OD, The Source of the Irritation By Elyse L. Chaglasian, OD, and Paul M. Karpecki, OD and Tammy P. Than, OD, MS 10 The GP Expert Surveyor of the Surface By Stephanie L. Woo, OD 20 Corneal Consult 30 CE — The Hunt for Stemming the Tide Dry Eye Instigators By James Thimons, OD Treatment options that target infl ammatory mediators in the tear fi lm may help clinicians achieve victory over this often diffi cult to manage condition. Derail Dropouts 32 By Michelle M. Hessen, OD Patch It Up By Mile Brujic, OD, and Clinical image on the cover courtesy of Mark Abelson, MD/Ora, Inc. Jason R. Miller, OD, MBA 34 Out of the Box Can’t We All Just Get Along? By Gary Gerber, OD REVIEW OF CORNEA & CONTACT LENSES | MAY 2014 3 /ReviewofCorneaAndContactLenses #rcclmag 003_rccl0514_TOC (v2).indd 3 4/25/14 4:57 PM News Review IN BRIEF A New Treatment for • Google has applied for a pat- Allergic Conjunctivitis? ent to fit a camera into a contact lens. According to the application, inserting the camera into the lens se of tacrolimus score decreased to 5.9. The mean will not dramatically increase the 0.1% eye drops is total score of clinical symptoms thickness of the lens. The addition of cameras will allow the lenses highly effective in decreased from 8.1 at baseline to process images and collect a treating refractory to 1.8 at fi nal observation. Ad- variety of data, such as motion, U allergic conjuncti- ditionally, both giant papillae colors, face, etc. Additionally, the vitis, according to a study pub- and corneal lesions were reduced contact lenses may include sen- lished in the April 2 online British signifi cantly (p<0.001) following sors that would be used to track blinking, which could be used to Journal of Ophthalmology. use of tacrolimus 0.1%. control or trigger devices remote- The prospective observational Prior to initiating tacrolimus ly via blinks. study evaluated the eyes of 1,436 therapy, 239 patients were treated patients with refractory aller- with cyclosporine 0.1% eye drops • Johnson & Johnson announced gic conjunctivitis who did not for at least one month; these pa- that the company is now accept- respond favorably to prior treat- tients exhibited giant papillae or ing research proposals related to meibography and tear film ment with conventional allergy corneal epithelial disorder scores stability with contact lens wear. drugs, topical steroids and/or greater than two at initiation of Specifically, J&J is looking for topical cyclosporine. treatment. Following one month research proposals in the areas During the trial, tacrolimus of tacrolimus use their clinical of correlating clinical findings to 0.1% drops were administered signs score decreased from 16.8 to meibomian gland image analysis and tear film stability, and cat- twice daily to each patient. The 6.7, and their clinical symptoms egorizing the magnitude of mei- researchers rated 10 clinical signs score decreased from 9.1 to 1.9. bomian gland changes to contact (palpebral conjunctiva hyperemia, The researchers noted adverse lens type or length of wear. To diffuse edema, follicles, papillae, reactions in 117 patients, with the inquire about proposal submis- giant papillae, bulbar conjunctiva only major reaction being a burn- sion, contact the Clinical Research Administrator at RA-VISUS- hyperemia, bullous edema, limbal ing sensation (45 cases). [email protected]. trantas’ dot, swelling and corneal Additionally, two cases of epithelial signs) and six clinical bacterial keratitis, two cases of • Smoking tobacco has a nega- symptoms (itching, discharge, herpetic keratitis and one case of tive impact on the healing lacrimation, photophobia, foreign bacterial corneal ulceration were process of corneal insults. In a body sensation and eye pain) on a observed. Atopic dermatitis or study published in the May 2014 Cornea, researchers reviewed the four-grade scale (0=none, 1=mild, asthma was noted as an underly- charts of 87 patients with corneal 2=moderate and 3=severe). ing condition in these cases. abrasions and 52 patients with Patients were graded at base- Initially developed as an immu- keratitis between 1990 and 2010. line, one month, two months, nosuppressant for use following The study demonstrated that three months and six months. The organ transplantation, tacrolimus epithelial healing is delayed 1.1 days on average in smokers vs. total score of both the 10 clinical is now used clinically for multiple non-smokers, and 23.9 days on signs (range 0-30) and six clinical immune-mediated conditions. The average in smokers with keratitis. symptoms (range 0-18) decreased researchers suggest that the use of Additionally, neurotrophic corneas signifi cantly from baseline to the topical tacrolimus is both safe and and fungal infections also exhib- one-month evaluation (p<0.001), effective in treating patients with ited a prolonged healing period in smokers. indicating the agent’s ability to severe allergic conjunctivitis. provide rapid relief. Fukushima A, et al. Therapeutic effects of Jetton JA, et al. Effects of tobacco At baseline, the mean total 0.1% tacrolimus eye drops for refractory aller- smoking on human corneal wound gic ocular diseases with proliferative lesion or healing. Cornea. 2014 May;33(5):453-6. score of clinical signs was 15.3; at corneal involvement. Br J Ophthalmol. 2014 fi nal observation, the mean total Apr 2. [Epub ahead of print] 4 REVIEW OF CORNEA & CONTACT LENSES | MAY 2014 004_rccl0514_news.indd 4 4/25/14 5:11 PM RCCL REVIEW OF CORNEA & CONTACT LENSES JOBSON PROFESSIONAL PUBLICATIONS GROUP 11 Campus Blvd., Suite 100 Newtown Square, PA 19073 Telephone (610) 492-1000 A Balanced Dry Eye Diet Fax (610) 492-1049 Editorial inquiries (610) 492-1003 Advertising inquiries (610) 492-1011 E-mail [email protected] Mediterranean diet D was inversely correlated with EDITORIAL STAFF may actually have a the infl ammatory marker soluble EDITOR-IN-CHIEF negative effect on dry interleukin-2 receptor. Jack Persico [email protected] eye symptoms, while Each patient was asked to fi ll ASSOCIATE EDITOR A Frank Auletto [email protected] increased intake of vitamin D may out a 2005 Block Food Frequency CLINICAL EDITOR have a small but positive effect, Questionnaire and the 5-item Dry Joseph P. Shovlin, OD, [email protected] EXECUTIVE EDITOR according to a study published in Eye Questionnaire. Additionally, Arthur B. Epstein, OD, [email protected] the May 2014 Cornea. an ocular surface examination ASSOCIATE CLINICAL EDITOR Two hundred forty-seven male consisting of tear osmolarity Christine W. Sindt, OD, [email protected] CONSULTING EDITOR patients between 55 and 95 years evaluation, tear break-up time, Milton M. Hom, OD, [email protected] old (mean age 69) at the Miami corneal staining, Schirmer’s test SENIOR ART/PRODUCTION DIRECTOR Joe Morris [email protected] Veteran’s Affairs eye clinic with was conducted on each patient. GRAPHIC DESIGNER normal eyelid, corneal and con- Patients who adhered to the Matt Egger [email protected] junctival anatomy were recruited Mediterranean diet were actually AD PRODUCTION MANAGER Scott Tobin [email protected] to undergo dry eye testing follow- found to have an increased risk of BUSINESS STAFF ing dietary changes. dry eye (p=0.007). Patients who VICE PRESIDENT OPERATIONS The subjects adhered to the reported a higher Mediterranean Casey Foster [email protected] Mediterranean diet, which in- diet score on the food frequency SALES MANAGER, NORTHEAST, MID ATLANTIC, OHIO cludes a relatively high intake of questionnaire (i.e., those who James Henne [email protected] fruits, vegetables, monounsaturat- adhered to the plan) demonstrated SALES MANAGER, SOUTHEAST, WEST Michele Barrett [email protected] ed fat, fi sh, whole grains, legumes abnormal meibum quality, abnor- and nuts, as well as moderate mal staining and higher Schirmer’s EDITORIAL BOARD Mark B.
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0152273 A1 Merchant Et Al
    US 20170152273A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0152273 A1 Merchant et al. (43) Pub. Date: Jun. 1, 2017 (54) TOPCAL PHARMACEUTICAL Publication Classification FORMULATIONS FOR TREATING (51) Int. Cl. NFLAMMLATORY-RELATED CONDITIONS C07F 5/02 (2006.01) Applicant: A6II 47/06 (2006.01) (71) Anacor Pharmaceuticals Inc., New A69/06 (2006.01) York, NY (US) A6IR 9/00 (2006.01) (72) Inventors: Tejal Merchant, Cupertino, CA (US); A6II 47/8 (2006.01) Dina Jean Coronado, Danville, CA A6II 45/06 (2006.01) (US); Charles Edward Lee, Union A6II 47/10 (2006.01) City, CA (US); Delphine Caroline A6II 3/69 (2006.01) Imbert, Cupertino, CA (US); Sylvia (52) U.S. Cl. Zarela Yep, Milpitas, CA (US) CPC .............. C07F 5/025 (2013.01); A61K 47/10 (2013.01); A61K 47/06 (2013.01); A61K3I/69 (73) Assignee: Anacor Pharmaceuticals Inc., New (2013.01); A61K 9/0014 (2013.01); A61 K York, NY (US) 47/183 (2013.01); A61K 45/06 (2013.01); A61K 9/06 (2013.01); C07B 2.200/13 (21) Appl. No.: 15/364,347 (2013.01) (22) Filed: Nov. 30, 2016 (57) ABSTRACT Related U.S. Application Data (60) Provisional application No. 62/420,987, filed on Nov. Topical pharmaceutical formulations, and methods of treat 11, 2016, provisional application No. 62/260,716. ing inflammatory conditions with these formulations, are filed on Nov. 30, 2015. disclosed. Patent Application Publication Jun. 1, 2017. Sheet 1 of 4 US 2017/0152273 A1 ?zzzzzzzzzzzzzzzzzzzzzzzzzzzz ????????????????????????????????????????????????????????????????????? S&S&S Šx&N Sssssssssssssssssssssssssssssssssssssss (r) eqn. O. peppy jeeNA go eunO/A Patent Application Publication Jun.
    [Show full text]
  • W W W .Bio Visio N .Co M New Products Added in 2020
    New products added in 2020 Please find below a list of all the products added to our portfolio in the year 2020. Assay Kits Product Name Cat. No. Size Product Name Cat. No. Size N-Acetylcysteine Assay Kit (F) K2044 100 assays Human GAPDH Activity Assay Kit II K2047 100 assays Adeno-Associated Virus qPCR Quantification Kit K1473 100 Rxns Human GAPDH Inhibitor Screening Kit (C) K2043 100 assays 20 Preps, Adenovirus Purification Kit K1459 Hydroxyurea Colorimetric Assay Kit K2046 100 assays 100 Preps Iodide Colorimetric Assay Kit K2037 100 assays Aldehyde Dehydrogenase 2 Inhibitor Screening Kit (F) K2011 100 assays Laccase Activity Assay Kit (C) K2038 100 assays Aldehyde Dehydrogenase 3A1 Inhibitor Screening Kit (F) K2060 100 assays 20 Preps, Lentivirus and Retrovirus Purification Kit K1458 Alkaline Phosphatase Staining Kit K2035 50 assays 100 Preps Alpha-Mannosidase Activity Assay Kit (F) K2041 100 assays Instant Lentivirus Detection Card K1470 10 tests, 20 tests Beta-Mannosidase Activity Assay Kit (F) K2045 100 assays Lentivirus qPCR Quantification Kit K1471 100 Rxns 50 Preps, Buccal Swab DNA Purification Kit K1466 Maleimide Activated KLH-Peptide Conjugation Kit K2039 5 columns 250 Preps Methionine Adenosyltransferase Activity Assay Kit (C) K2033 100 assays CD38 Activity Assay Kit (F) K2042 100 assays miRNA Extraction Kit K1456 50 Preps EZCell™ CFDA SE Cell Tracer Kit K2057 200 assays MMP-13 Inhibitor Screening Kit (F) K2067 100 assays Choline Oxidase Activity Assay Kit (F) K2052 100 assays Mycoplasma PCR Detection Kit K1476 100 Rxns Coronavirus
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Review Article Barrier-Restoring Therapies in Atopic Dermatitis: Current Approaches and Future Perspectives
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Crossref Hindawi Publishing Corporation Dermatology Research and Practice Volume 2012, Article ID 923134, 6 pages doi:10.1155/2012/923134 Review Article Barrier-Restoring Therapies in Atopic Dermatitis: Current Approaches and Future Perspectives Y. Valdman-Grinshpoun,1, 2 D. Ben-Amitai,1, 3 and A. Zvulunov1, 4 1 Pediatric Dermatology Unit, Schneider Children’s Medical Center of Israel, 49202 Petach Tikva, Israel 2 Department of Dermatology, Szold Health Center, Clalit Health Services, 84894 Beer-Sheva, Israel 3 Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel 4 Medical School for International Health, Faculty of Medicine, Ben-Gurion University of the Negev, 84105 Beer-Sheva, Israel Correspondence should be addressed to Y. Valdman-Grinshpoun, [email protected] Received 21 April 2012; Accepted 18 June 2012 Academic Editor: Georgios Stamatas Copyright © 2012 Y. Valdman-Grinshpoun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Atopic dermatitis is a multifactorial, chronic relapsing, inflammatory disease, characterized by xerosis, eczematous lesions, and pruritus. The latter usually leads to an “itch-scratch” cycle that may compromise the epidermal barrier. Skin barrier abnormalities in atopic dermatitis may result from mutations in the gene encoding for filaggrin, which plays an important role in the formation of cornified cytosol. Barrier abnormalities render the skin more permeable to irritants, allergens, and microorganisms. Treatment of atopic dermatitis must be directed to control the itching, suppress the inflammation, and restore the skin barrier.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0235763 A1 Budunova Et Al
    US 2016O235763A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0235763 A1 BudunOVa et al. (43) Pub. Date: Aug. 18, 2016 (54) USE OF REDD1 INHIBITORSTO Publication Classification DISSOCATE THERAPEUTIC AND ADVERSE ATROPHOGENCEFFECTS OF (51) Int. Cl. GLUCOCORTICOD RECEPTORAGONSTS A613 L/56 (2006.01) A613 L/713 (2006.01) (71) Applicant: Northwestern University, Evanston, IL A613 L/436 (2006.01) (US) (52) U.S. Cl. CPC ............... A61 K3I/56 (2013.01); A61 K3I/436 (72) Inventors: Irina Budunova, Chicago, IL (US); (2013.01); A61 K3I/713 (2013.01) Gleb Baida, Chicago, IL (US); Joel Dudley, Rye, NY (US) (57) ABSTRACT (73) Assignee: Northwestern University, Evanston, IL (US) Disclosed are methods and pharmaceutical compositions for treating diseases, disorders, and conditions associated with (21) Appl. No.: 15/046,075 glucocorticoid receptor (GR) expression and activity. The disclosed methods typically include administering to a (22) Filed: Feb. 17, 2016 patient in need thereofaglucocorticoid receptor (GR) agonist and administering to the patient in need thereof a REDD1 Related U.S. Application Data inhibitor that inhibits expression or activity of REDD1, (60) Provisional application No. 62/117,248, filed on Feb. wherein the REDD1 inhibitor is administered before, concur 17, 2015. rently with, or after the GRagonist is administered. Patent Application Publication Aug. 18, 2016 Sheet 1 of 17 US 2016/0235763 A1 Figre s: S. 48 :383.3 ge is: 8xx xx & s SS s sa a:23 8x3: & 25 88: c s S: 3 3 : 88 s : 3. s 3 : 3S s is $8 3S. .'ss& 3S citos. 8d.: Patent Application Publication Aug.
    [Show full text]
  • Emmett Cunningham, Jr., M.D., Ph.D., M.P.H
    2019 - Emmett Cunningham, Jr., M.D., Ph.D., M.P.H. Senior Managing Director Blackstone Life Sciences HEATHEGY TEAM CRAIG SIMAK CRAIG SIMAK DANIELLE SILVA MAUREEN LINNEMANN 1200 OIS@AAO 24 Meetings > 1,150 1000 ~ 13,500 Attendees 800 OIS@ASCRS 600 > 650 400 OIS@ASRS 200 > 300 0 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 Registrants 3% 10% OIS@AAO 2019 ( > 1,150) 8% Academia, Government, or Association 41% Adviser, Consultant, or Service Provider Finance/Investment Firm Large Multi-National Corporation Physician/Healthcare Provider 25% Press/Media Start-up/Emerging Growth Company 3% 25 Countries 10% 32 US States Record Number of CDER NME NDA/BLA Approvals in 2018 70 BLA 59 60 NDA 50 45 46 Number 39 41 of 40 35 36 Drugs 30 30 30 27 27 24 26 22 24 21 20 21 22 20 17 18 10 0 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 Source: FDA 1998 - 2018 High Innovation Record Number of • 31 (53%) Orphan CDER NME NDA/BLA Approvals in 2018 • 26 (44%) Priority Review • 16 (27%) Fast Track • 12 (20%) Break Through Designation 59 • 18 (30%) Oncology • 1 (0%) Ophthalmology Cenegermin-bkbj Ophthalmic Solution, (OXERVATE®) Ophthalmic Drugs Streamlined Reporting of Ophthalmology Clinical Group CDER As of January, 2018 Ophthalmology Clinical Group Reported Directly & Independently to Deputy Director Office of New Drugs Peter Stein, MD Five Additional Office of Offices of Drug Antimicrobial Evaluation (ODEs) Products Division of Division of Division of Transplant and Anti-Infective Anti-Viral Ophthalmology Products Products Dr.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Selective Glucocorticoid Receptor Properties of GSK866 Analogs with Cysteine Reactive Warheads
    ORIGINAL RESEARCH published: 01 November 2017 doi: 10.3389/fimmu.2017.01324 Selective Glucocorticoid Receptor Properties of GSK866 Analogs with Cysteine Reactive Warheads Edited by: 1 1† 2 1 Jixin Zhong, Chandra S. Chirumamilla , Ajay Palagani , Balu Kamaraj , Ken Declerck , 1 3 4 4 Case Western Reserve University, Marinus W. C. Verbeek , Ryabtsova Oksana , Karolien De Bosscher , Nadia Bougarne , United States Bart Ruttens 5, Kris Gevaert 5, René Houtman 6, Winnok H. De Vos 7, Jurgen Joossens 3, 3 3 1 2 Reviewed by: Pieter Van Der Veken , Koen Augustyns , Xaveer Van Ostade , Annemie Bogaerts , 3 1 Yanlin He, Hans De Winter and Wim Vanden Berghe * Baylor College of Medicine, 1 United States Laboratory of Protein Chemistry, Proteomics and Epigenetic Signalling, Department of Biomedical Sciences, University of 2 Penghua Yang, Antwerp, Antwerp, Belgium, Research Group PLASMANT, Department of Chemistry, University of Antwerp, Antwerp, 3 University of Maryland, Belgium, Medicinal Chemistry, Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium, 4 United States Receptor Research Laboratories, Nuclear Receptor Lab (NRL) and Cytokine Receptor Lab (CRL), VIB-UGent Center for 5 Shanzhong Gong, Medical Biotechnology, Ghent University, Ghent, Belgium, Center for Medical Biotechnology, Department of Biochemistry, 6 7 University of Texas at Austin, VIB, Ghent University, Ghent, Belgium, PamGene International B.V., Den Bosch, Netherlands, Laboratory of Cell Biology United States and Histology, Department of Veterinary Sciences,
    [Show full text]
  • Linker Payload Contribution in GR Activation of Steroid-ADC As Tested in HEK293/PRLR/GRE-Luc Cells
    ( (51) International Patent Classification: HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, A61K 47/68 (2017.01) C07J 71/00 (2006.01) KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/US20 19/0 12786 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (22) International Filing Date: TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 08 January 2019 (08.01.2019) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available) . ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (26) Publication Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (30) Priority Data: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 62/614,905 08 January 2018 (08.01.2018) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (71) Applicant: REGENERON PHARMACEUTICALS, TR), OAPI (BF, BJ, CF, CG, Cl, CM, GA, GN, GQ, GW, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, KM, ML, MR, NE, SN, TD, TG). New York 10591 (US). (72) Inventor: HAN, Amy; c/o Regeneron Pharmaceuticals, Declarations under Rule 4.17: Inc., 777 Old Saw Mill River Road, Tarrytown, New York — as to the identity of the inventor (Rule 4.17(i)) 10591-6707 (US).
    [Show full text]
  • Efficacy and Safety of Fixed-Dose Combination Calcipotriol/ Betamethasone Dipropionate Foam for the Treatment of Psoriasis
    Henry Ford Health System Henry Ford Health System Scholarly Commons Dermatology Articles Dermatology 2-1-2021 Efficacy and safety of fixed-dose combination calcipotriol/ betamethasone dipropionate foam for the treatment of psoriasis Linda F. Stein Gold Carle Paul Ricardo Romiti Follow this and additional works at: https://scholarlycommons.henryford.com/dermatology_articles DOI: 10.1111/jdv.17028 JEADV SUPPLEMENT ARTICLE Efficacy and safety of fixed-dose combination calcipotriol/betamethasone dipropionate foam for the treatment of psoriasis L. Stein Gold1,* , C. Paul,2 R. Romiti3 1Department of Dermatology, Henry Ford Hospital, Detroit, MI, USA 2Department of Dermatology, Toulouse University and CHU, Toulouse, France 3Department of Dermatology, Hospital das Clinicas, University of Sao Paulo, Sao Paulo, Brazil *Correspondence: L. Stein Gold. E-mail: [email protected] Abstract The fixed-dose combination calcipotriol (Cal; 50 µg/g) plus betamethasone dipropionate (BD; 0.5 mg/g) ointment and gel formulations have well-established efficacy profiles in the treatment of psoriasis vulgaris (chronic plaque psoriasis); this combination has been shown to produce favourable outcomes versus either monotherapy. To improve upon the effi- cacy and cosmetic acceptability of these treatments Cal/BD foam was developed, demonstrating superior efficacy in Phase II/III studies compared with either of its monocomponents, Cal/BD ointment, Cal/BD gel and various other thera- pies for the treatment of psoriasis. Multiple outcome measures were evaluated in the clinical studies, including physi- cian’s global assessment of disease severity and modified psoriasis area and severity index. Of note, 38–55% of patients across studies achieved a physician’s global assessment of ‘clear’ or ‘almost clear’ after 4 weeks of Cal/BD treatment.
    [Show full text]
  • WHO Drug Information Vol
    WHO Drug Information Vol. 23, No. 4, 2009 World Health Organization WHO Drug Information Contents International Nonproprietary Prequalification of Medicines Names Programme INN identifiers for biological products 273 Prequalification of quality control laboratories 300 Safety and Efficacy Issues Rituximab: multifocal leuko- Pharmacovigilance Focus encephalopathy 282 A/H1N1 vaccination safety: PaniFlow® Darbepoetin alfa: risk of stroke 282 surveillance tool 305 Vigabatrin and movement disorders 283 Alendronate: risk of low-energy femoral Regulatory Action and News shaft fracture 283 Influenza vaccines for 2010 southern Ceftriaxone and calcium containing hemisphere winter 306 solutions 284 Romidepsin: approved for cutaneous Etravirine: severe skin and hyper- T-cell lymphoma 306 sensitivity reactions 285 Orciprenaline sulphate: withdrawal 306 Oseltamivir phosphate: dosing risk 285 Artemisinin antimalarials: not for Safety signal: hyponatraemia 286 use as monotherapy 307 Clopidogrel and omeprazole: reduced Vitespen: withdrawal of marketing effectiveness 286 authorization application 307 Bisphosphonates: osteonecrosis of Aripiprazole: withdrawal of application the jaw 287 for extension of indication 307 Intravenous promethazine: serious Substandard and counterfeit medicines: tissue injuries 287 USAID–USP Agreement 308 Cyproterone: risk of meningiomas 288 Vandetinib: withdrawal of marketing Gadolinium-containing contrast agents 289 authorization application 308 Cesium chloride: cardiac risks 290 Washout or taper when switching antidepressants
    [Show full text]
  • WO 2016/051188 Al 7 April 2016 (07.04.20 16) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/051188 Al 7 April 2016 (07.04.20 16) W P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 213/74 (2006.01) A61P 29/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/44 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/GB20 15/052877 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 1 October 2015 (01 .10.2015) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1417344.7 1 October 2014 (01. 10.2014) GB kind of regional protection available): ARIPO (BW, GH, 15 10694. 1 18 June 2015 (18.06.2015) GB GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicants: RESPFVERT LIMITED [GB/GB]; 50-100 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Holmers Farm Way, High Wycombe, Buckinghamshire DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, HP 12 4EG (GB).
    [Show full text]